Early 7-day supplemental parenteral nutrition improves body composition and muscle strength in hypophagic cancer patients at nutritional risk
Riccardo Caccialanza(University of Pavia), Paolo Pedrazzoli(Policlinico San Matteo Fondazione), Luca Arcaini(University of Pavia), Valeria Borioli(Istituti di Ricovero e Cura a Carattere Scientifico), Jessica Saddi(Policlinico San Matteo Fondazione), Marilisa Caraccia(Policlinico San Matteo Fondazione), Angioletta Lasagna(University of Pavia), Vittorina Zagonel(Istituto Oncologico Veneto), Silvia Cappello(Ludwig-Maximilians-Universität München), Ilaria Imarisio(University of Pavia), Catherine Klersy(Policlinico San Matteo Fondazione), Silvia Stragliotto(Istituto Oncologico Veneto), Marco Benazzo(University of Pavia), Emanuele Cereda(GTx (United States)), Mariateresa Nardi(Istituti di Ricovero e Cura a Carattere Scientifico), Annalisa Turri(Policlinico San Matteo Fondazione)
Cited by 49
Related Papers
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
|The Lancet Oncology|2018|2.5k
Initial Therapy with FOLFOXIRI and Bevacizumab for Metastatic Colorectal Cancer
|New England Journal of Medicine|2014|1.1k
Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial
|The Lancet Oncology|2016|1k